Gene technology will soon render it possible to make recombinant human serum albumin for clinical use, to produce albumins with altered biological half-lives and isoforms with such high and specific binding affinity that they may be used as antidotes. Mutants with increased affinity for different cell types can be designed and used for drug targeting… (More)